Maven Securities LTD Invests $1.22 Million in Myriad Genetics, Inc. (NASDAQ:MYGN)

Maven Securities LTD purchased a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 50,000 shares of the company's stock, valued at approximately $1,223,000. Maven Securities LTD owned approximately 0.06% of Myriad Genetics at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Hexagon Capital Partners LLC lifted its stake in shares of Myriad Genetics by 75.3% during the 2nd quarter. Hexagon Capital Partners LLC now owns 1,143 shares of the company's stock valued at $28,000 after buying an additional 491 shares in the last quarter. Innealta Capital LLC purchased a new stake in Myriad Genetics in the 2nd quarter worth approximately $36,000. Point72 DIFC Ltd purchased a new stake in Myriad Genetics in the 2nd quarter worth approximately $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Myriad Genetics in the 2nd quarter worth approximately $82,000. Finally, Neo Ivy Capital Management purchased a new stake in Myriad Genetics in the 2nd quarter worth approximately $85,000. 99.02% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Heinrich Dreismann sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $27.05, for a total value of $270,500.00. Following the completion of the transaction, the director now owns 121,648 shares in the company, valued at approximately $3,290,578.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Colleen F. Reitan sold 46,012 shares of the business's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the sale, the director now owns 42,533 shares of the company's stock, valued at $1,188,797.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Heinrich Dreismann sold 10,000 shares of the business's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $27.05, for a total transaction of $270,500.00. Following the sale, the director now directly owns 121,648 shares in the company, valued at approximately $3,290,578.40. The disclosure for this sale can be found here. 2.10% of the stock is owned by insiders.

Myriad Genetics Trading Down 0.3 %

Shares of MYGN traded down $0.07 during mid-day trading on Wednesday, hitting $26.96. 503,379 shares of the company's stock traded hands, compared to its average volume of 720,519. The company has a quick ratio of 1.78, a current ratio of 1.96 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $2.44 billion, a P/E ratio of -9.56 and a beta of 1.92. The business's 50-day moving average price is $27.42 and its 200-day moving average price is $24.38. Myriad Genetics, Inc. has a 1 year low of $13.82 and a 1 year high of $29.30.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $0.06. Myriad Genetics had a negative net margin of 19.35% and a negative return on equity of 5.64%. The business had revenue of $211.50 million for the quarter, compared to the consensus estimate of $206.44 million. During the same period in the previous year, the firm earned ($0.21) EPS. The company's quarterly revenue was up 15.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Myriad Genetics, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MYGN has been the topic of several recent analyst reports. JPMorgan Chase & Co. increased their target price on shares of Myriad Genetics from $17.00 to $20.00 and gave the stock an "underweight" rating in a research note on Wednesday, August 7th. Morgan Stanley initiated coverage on shares of Myriad Genetics in a research note on Thursday, September 19th. They issued an "equal weight" rating and a $32.00 target price on the stock. TD Cowen increased their target price on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a "hold" rating in a research note on Wednesday, August 7th. Scotiabank increased their target price on shares of Myriad Genetics from $29.00 to $34.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, August 13th. Finally, Wells Fargo & Company began coverage on shares of Myriad Genetics in a report on Tuesday, August 27th. They issued an "overweight" rating and a $35.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Myriad Genetics currently has a consensus rating of "Hold" and a consensus price target of $28.91.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.